Eplerenone

Generic Name: Eplerenone

Brand Names: Inspra

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₀O_₆

CAS Number: 107724-20-9

Unique Ingredient Identifier: 6995V82D0B

Background: Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Indication: For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions: Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)

Associated Therapies: -

Clinical Trials

A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension

Phase 2

Terminated

Conditions: Hypertension

Interventions: Drug: Losartan
Drug: eplerenone

First Posted Date: 2008-04-01

Last Posted Date: 2009-12-01

Lead Sponsor: Pfizer

Target Recruit Count: 248

Registration Number: NCT00649311

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

Phase 2

Terminated

Conditions: Atrial Fibrillation

Interventions: Drug: Placebo
Drug: Eplerenone

First Posted Date: 2008-03-31

Last Posted Date: 2012-02-10

Lead Sponsor: University Hospital, Saarland

Target Recruit Count: 38

Registration Number: NCT00647192

Locations: 🇩🇪
Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany
🇳🇱
Rijksuniversiteit Groningen, Universitair Medisch Centrum, Groningen, Netherlands

Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

Phase 4

Terminated

Conditions: Metabolic Syndrome X

Interventions: Drug: Ramipril
Drug: Eplerenone

First Posted Date: 2008-02-06

Last Posted Date: 2017-08-11

Lead Sponsor: Vanderbilt University

Target Recruit Count: 4

Registration Number: NCT00608465

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?

Phase 4

Conditions: Hypertension
Dialysis
Hyperaldosteronism

Interventions: Drug: Eplerenone
Drug: Placebo

First Posted Date: 2007-11-06

Last Posted Date: 2007-11-06

Lead Sponsor: Shaare Zedek Medical Center

Target Recruit Count: 27

Registration Number: NCT00553722

Locations: 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel

The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure

Not Applicable

Completed

Conditions: Diastolic Heart Failure

Interventions: Drug: Eplerenone
Other: No additional treatment
Drug: Atorvastatin

First Posted Date: 2007-07-23

Last Posted Date: 2009-02-11

Lead Sponsor: St Vincent's University Hospital, Ireland

Target Recruit Count: 43

Registration Number: NCT00505336

Locations: 🇮🇪
St Vincent's University Hospital, Ballsbridge, Dublin, Ireland

Inhibition of Aldosterone in Patients With Chronic Renal Disease

Phase 4

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Eplerenone

First Posted Date: 2007-02-02

Last Posted Date: 2012-02-08

Lead Sponsor: Lene Boesby

Target Recruit Count: 42

Registration Number: NCT00430924

Locations: 🇩🇰
Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark
🇩🇰
Herlev Hospital, Herlev, Denmark

Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.

Conditions: Hyperaldosteronism
Hypertension

First Posted Date: 2006-12-05

Last Posted Date: 2007-03-07

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 500

Registration Number: NCT00407784

Locations: 🇳🇱
Academical Medical Center, Amsterdam, Netherlands
🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇳🇱
Sint Franciscus Gasthuis, Rotterdam, Netherlands

and more 10 locations

CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone

Phase 4

Completed

Conditions: Cardiomyopathy

Interventions: Drug: Eplerenone
Drug: Placebo

First Posted Date: 2006-11-22

Last Posted Date: 2021-09-21

Lead Sponsor: Royal Brompton & Harefield NHS Foundation Trust

Target Recruit Count: 42

Registration Number: NCT00401856

Locations: 🇬🇧
Royal Brompton & Harefield NHS Trust, London, United Kingdom

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

Eplerenone, ACE Inhibition and Albuminuria

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: placebo
Drug: eplerenone
Drug: fosinopril

First Posted Date: 2006-04-17

Last Posted Date: 2012-05-28

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 30

Registration Number: NCT00315016

Locations: 🇳🇱
Jeroen Bosch Hospital, 's-Hertogenbosch, Noord Brabant, Netherlands
🇳🇱
University Medical Center Nijmegen St Radboud, Nijmegen, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy